Background/Objectives: Penile urethral stricture is a therapeutically challenging condition that significantly impacts quality of life and is often managed initially with urethral dilation or internal urethrotomy. However, both techniques are associated with high recurrence rates, limited long-term efficacy, and potential adverse effects, particularly in the penile urethra. Urethroplasty remains the gold standard but is invasive and not suitable for all patients. Optilume, a paclitaxel-coated balloon, combines mechanical dilation with localized drug delivery to reduce recurrence rates and the need for re-intervention. This study evaluated its effectiveness in patients with penile urethral strictures. Methods: A retrospective, multicenter study was conducted at two German clinics. Eight male patients (mean age 59) with symptomatic penile urethral strictures underwent Optilume treatment. Symptom severity was assessed using the International Prostate Symptom Score (IPSS) and quality of life (QoL) scores before and after treatment. The primary endpoint was symptom improvement, while the secondary endpoint was the need for reintervention. Patients were followed for a median of 16.5 months. Statistical analyses included Wilcoxon signed-rank and Mann–Whitney U tests. Results: The median IPSS improved from 25.5 to 5.0 and QoL scores from 4.5 to 1.0 after treatment (p < 0.01 for both). No patients required reintervention during follow-up. The subgroup analysis showed slightly better outcomes in patients without prior interventions, although differences were not statistically significant. The stricture length did not correlate with treatment response. Conclusions: Optilume significantly reduces urinary symptoms and improves QoL in penile urethral strictures, and the absence of re-interventions during follow-up underscores its durable mid-term success. It offers a minimally invasive alternative to urethroplasty, particularly for patients seeking symptom relief with a shorter recovery time and no hospital stay or general anesthesia. These preliminary findings suggest that Optilume may be a promising minimally invasive option for selected patients. Larger, controlled studies are warranted to validate these results and refine patient selection criteria.

The correlation between progression and the genetic characteristics of Binet stage A patients with chronic lymphocytic leukemia (CLL) detected by whole exome sequencing (WES) was analyzed in 55 patients. The median follow-up for the patients was 102 months. During the follow-up, 24 patients (43%) progressed. Univariate Cox analysis showed that the presence of driver mutations, the accumulation of two or more mutations, the presence of adverse mutations, immunoglobulin heavy chain genes (IGHV) mutation status and unfavorable single copy number abnormalities (SCNAs) were associated with a higher risk of progression. Particularly, the occurrence of an adverse mutation and unfavorable SCNAs increased the risk of progression nine-fold and five-fold, respectively. Nevertheless, only the occurrence of adverse mutations retained statistical significance in the multivariate analysis. All patients carrying an unfavorable mutation progressed with a median progression-free survival (PFS) of 29 months. The accumulation of two or more mutations also increased the risk of progression with a median PFS of 29 months. The median PFS of patients with unfavorable SCNAs was 38 months. Combining mutations and SCNAs, patients may be stratified into three groups with different prognostic outcomes: adverse (17% probability of five-year PFS), protective (86% probability of five-year PFS) and neither (62% probability of five-year PFS, p < 0.001). Overall, the analysis of the mutational status of patients with CLL at an early stage of the disease may allow the identification of patients with a high risk of progression. The feasibility of an early therapeutic intervention in these particular patients requires further investigation.

Background: Bulbar urethral strictures are a common cause of lower urinary tract symptoms (LUTSs) in men and frequently recur after standard endoscopic treatments. There is growing interest in identifying less invasive techniques that provide durable outcomes compared to conventional endoscopic methods. Optilume has shown favorable outcomes in prospective trials, but real‐world evidence, especially including treatment‐naïve patients, remains limited. Methods: We performed a retrospective study in two German urology practices, including 40 men with symptomatic bulbar urethral strictures. Symptoms were assessed using the International Prostate Symptom Score (IPSS) and IPSS‐derived quality‐of‐life (QoL) score at baseline and at follow‐up. The primary endpoints were changes in IPSS and QoL; secondary endpoints included reintervention and safety. Nonparametric paired testing (Wilcoxon) and correlation analysis (Pearson) were applied. Results: Median follow‐up was 29.5 months. IPSS improved from a median of 19.5 (2–35) to 6.0 (0–26), and QoL improved from 5.0 (0–6) to 1.0 (0–5) ( p < 0.000001). The median absolute change was ΔIPSS −10.5 overall; ΔIPSS was −16.5 in treatment‐naïve patients and −9.5 in previously treated patients. Median ΔQoL was −4.0 overall (−3.5 treatment‐naïve; −4.0 previously treated). One patient (2.5%) was scheduled for reintervention due to subjective dissatisfaction despite IPSS improvement. Treatment‐naïve patients showed a trend toward better outcomes. Conclusions: Optilume demonstrated excellent mid‐term outcomes (median follow‐up: 29.5 months) in the treatment of bulbar urethral strictures, with significant improvements in symptom burden and QoL and a low reintervention rate (2.5%) in a real‐world two‐center cohort with a nonsignificant trend toward greater symptomatic improvement in treatment‐naïve individuals. These findings support Optilume as a viable minimally invasive option. Larger prospective studies incorporating stricture‐specific patient‐reported outcome measures and comparative designs are needed to confirm long‐term effectiveness, cost considerations, and optimal patient selection.